This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Greg Hoffman, PhD
Chief Scientific Officer at Deep Genomics
Speaker

Profile

Greg Hoffman is the Chief Scientific Officer at Deep Genomics, leading the team responsible for generating rich data sets to train and validate our AI platform by applying state of the art capabilities in cell biology, molecular biology, robotics, screening, and animal models. Greg and his team play a key strategic role collaborating with our internal machine learning team and external partners to identify novel applications of our AI platform to address key unmet needs in target discovery and therapeutics development for RNA-biology.

Greg brings over 20 years of experience in the biotechnology and pharmaceutical sector, including leadership roles at Arbor Biotechnology, Obsidian Therapeutics, Sana Biotechnology, and Novartis. Greg is an experienced leader in building innovative technology platforms to uncover mechanisms of human disease and develop novel therapeutics, working at the interface of biology and computational methods in multiple disciplines including structural biology, functional genomics, gene editing, and development of cell and gene therapies

Agenda Sessions

  • Applying Machine Learning to Identify Differentiated Target Mechanisms and Design Next-Generation Oligonucleotide Therapeutics

    10:45am